West Pharmaceutical Services, Inc. (WST) Income Statement

The reacceleration from the low single-digit growth seen in late 2024 and most of 2025 points to a recovery in biologics and high-value product demand rather than a mere comparison effect. The deceleration to 8.7% in Q3 relative to Q2 and Q1 warrants attention, since management's guided revenue range implies a sequential slowdown, which may reflect mix normalization or seasonality. Investors should monitor whether organic volume growth can hold above high single digits once contract-manufactured volumes begin to roll off.

The sustained step-up across eight quarters suggests structural rather than cyclical improvement, consistent with a higher proportion of proprietary elastomer and film-coated components in revenue. Because the Q3 2026 margin is the highest in the dataset, the question for analysts is whether raw material inflation or capacity under-absorption from new lines could compress it from here. Margin durability depends heavily on continued HVP adoption.

SG&A has grown far more slowly than gross profit over the period, which implies overhead is being absorbed by a larger revenue base rather than expanding in step. The 2026Q3 operating margin of 30.6% is a notable outlier relative to the 19.5% to 22.8% range seen through 2024 and 2025, and it may partly reflect a favorable one-quarter mix effect. Sustaining operating margins near this level would require the leverage to persist rather than revert.